Details for New Drug Application (NDA): 205525
✉ Email this page to a colleague
The generic ingredient in SYNDROS is dronabinol. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dronabinol profile page.
Summary for 205525
Tradename: | SYNDROS |
Applicant: | Benuvia |
Ingredient: | dronabinol |
Patents: | 4 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 205525
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 5MG/ML | ||||
Approval Date: | Mar 23, 2017 | TE: | RLD: | Yes | |||||
Patent: | See Plans and Pricing | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patent: | See Plans and Pricing | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patent: | See Plans and Pricing | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? |
Complete Access Available with Subscription